Prognia
Drug Database
🇪🇺EU · EMAOpinionATC: L01FX33Orphan Medicine

Imdylltra(tarlatamab)

Small Cell Lung Carcinoma

Marketing Authorisation Holder: Amgen Europe B.V.

INN: tarlatamab

Indication

Treatment of extensive-stage small cell lung cancer

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Imdylltra — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.